Sinopharm Holdings (01099) announced interim results, net profit of 3.404 billion yuan, a year-on-year decrease of 1.79%

According to the Zhitong Finance App, Sinopharm Holdings (01099) announced its 2026 interim results. The group achieved revenue of 282.8 billion yuan during the period, a year-on-year decrease of 1.13%; profit attributable to owners of the parent company was 3.404 billion yuan, a year-on-year decrease of 1.79%; and a basic profit of 1.09 yuan per share.

According to the announcement, the decrease in revenue was due to the decline in revenue from the Group's pharmaceutical distribution and device distribution business.

The Group's pharmaceutical distribution revenue during the reporting period was RMB 215.496 billion, down 1.39% from RMB 218.527 billion in the six months ended June 30, 2025, accounting for 72.98% of the Group's total revenue. The decline was mainly due to multiple factors such as volume procurement, red and yellow label price management, and health insurance supervision.

The Group's equipment distribution revenue during the reporting period was RMB 56.854 billion, down 0.35% from RMB 57.53 billion for the six months ended June 30, 2025, accounting for 19.25% of the Group's total revenue. The decline was mainly due to the decline in medical equipment sales revenue due to the implementation of centralized procurement policies for large-scale equipment in public medical institutions.